- Monitor assay performance across routine and specialised testing
- Verify reagent integrity and system functionality
- Ensure compliance with ISO 15189 and local regulatory standards (HPRA, UKAS)
- Reduce risk of transfusion errors and improve laboratory confidence
-
Precision. Confidence. Compliance. Technopath is proud to partner with Diagast, a global leader in immunohaematology, to deliver a comprehensive range of quality control solutions designed to ensure accuracy, reliability, and full regulatory compliance in transfusion laboratories with ISO 15189 requirements. Diagast’s immunohaematology quality control portfolio supports laboratories in maintaining the highest standards across blood grouping, antibody screening, crossmatching, and reagent performance verification—helping safeguard patient outcomes at every stage of the transfusion pathway. Comprehensive Quality Control for Transfusion Safety In immunohaematology, precision is critical. Diagast’s quality controls are specifically developed to: -
Confirm ABO Blood Group at patient bedside Safety Test ABO is a medical in vitro diagnostic device for professional use to confirm ABO blood group compatibility before a transfusion, at the patient's bedside. This testing comes in addition to patient identity checking and comparison between group on blood bag label and the patient’s group. The procedure is based on haemagglutination’s principles. Red blood cells carry antigens and agglutinate in the presence of test sera (reagents) carrying corresponding antibodies (colored reagents are dried out on the card’s wells). Safety Test ABO (Ref 79069) includes 100 single-use tests packed separately. A single test of Safety Test ABO consists of:- 1 Safety Card AB is individually packed in a sealed package 1 vial of NaCl 0,9% (physiological saline) 1 fingerprick lancet 1 segment opener 4 spatulas
- 1 x anti-A and 1 x anti-B for the patient on the card’s left side 1 x anti-A and 1 x anti-B for the blood bag on the card’s right side
-
Confirm ABO compatibility ABTest Card® is a device, from Diagast, for the confirmation of ABO compatibility between the patient and the blood unit to be transfused. Based on the M-TRAP® technology, it allows an easy and simple confirmation, safer for both user and patient. The red blood cells tested, carrying an antigen, interact with the related antibodies, revealing a red spot (positive reaction). The red blood cells that do not carry the antigen do not interact with the antibodies and cross the membrane. The spot will appear light green or white (negative reaction). If the red blood cells tested interact with the associated antibodies, the blood deposit remains. Red blood cells carry the desired antigens. It is a positive reaction. If the red blood cells tested do not interact with the associated antibodies, the blood deposit disappears. Red blood cells do not carry the desired antigens. It is a negative reaction. ABTest MULTI also offers a bedside test dedicated to emergency massive transfusions. This device allows to test once the patient to transfuse a maximum of 3 red blood cell (RBC) within 1 hour, allowing safety and traceability. -
Manual Techniques from Diagast Historically, hemagglutination methods are performed with liquid reagents on slide, opaline plates or tube supports. See below for the Diagast manual techniques offering and full list of immunohaematology methods. -
Blood Group Test using M-TRAP® Technology M-TRAP® Technology is based on the detection of antigen-antibody interaction on a porous membrane. Only the red blood cells having the corresponding antigen are fixed into the membrane revealing immediately the reaction. A breakthrough technology! The principle: The M-TRAP® Technology, patented by DIAGAST, relies on the superposition of membranes and has 2 major advantages:- Since the test antibodies are inside the upper membrane, they never get in direct contact with the user. There is no risk of cross-contamination.
- Since the lower membrane absorbs the liquids of the test (PAD Buffer and sample), the risk of blood exposure is considerably lower.
- This simple protocol takes place in 3 steps and in 30 seconds.
-
Extended phenotyping reagents for BECKMAN COULTER PK7300 & PK7400 Automated Microplate Systems The reagents of PK7300 are in vitro diagnostic medical devices (IVDMD) for professional use. They are exclusively intended for blood bag identification centres, such as blood banks. The reagents ANTI-Fya (FY1) PK, ANTI-Fyb (FY2) PK, ANTI-Jka (JK1) PK, ANTI-Jkb (JK2) PK, ANTI-M (MNS1) PK, ANTI-N (MNS2) PK, ANTI-S (MNS3) PK and ANTI-s (MNS4) PK are used for the extended phenotyping of human red blood cells. They detect the presence of antigens Fya (FY1), Fyb (FY2), Jka (JK1), Jkb (JK2), M (MNS1), N (MNS2), S (MNS3) and s (MNS4) on the surface of red blood cells. The CONTROL PK must be used in blood grouping or phenotyping. It is devoid of antibody activity. When tested under the same conditions as the reagents for PK®SYSTEM, the CONTROL PK enables the user to interpret the result obtained. These reagents are ready for use for BECKMAN COULTER PK7300 & PK7400 automated microplate systems. -
Innovation and flexibility for your immunohaematology automation DIAGAST, an international expert and specialist in transfusion diagnostics, has included innovation and flexibility in the QWALYS® 3 EVO automated system. With the E.M.® Technology, QWALYS® 3 EVO is the only fully-automated system on the market using the magnetisation of erythrocytes, a process that no longer requires washing and centrifugation steps. Latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS® 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centres and hospitals.
